tradingkey.logo
tradingkey.logo
検索

Coya Therapeutics Inc

COYA
ウォッチリストに追加
3.130USD
-0.140-4.28%
終値 11-13 16:00(ET)
73.43M時価総額
損失額直近12ヶ月PER
時間外取引 16:00 (ET)3.130USD-0.010-0.32%

Coya Therapeutics Incについて 企業名

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.

Coya Therapeutics Inc プロフィール

企業コードCOYA
会社名Coya Therapeutics Inc
上場日Dec 29, 2022
最高経営責任者「CEO」Swaminathan (Arun)
従業員数8
証券種類Ordinary Share
決算期末Dec 29
本社所在地5850 San Felipe St.
都市HOUSTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号77057
電話番号8005878170
ウェブサイトhttps://www.coyatherapeutics.com/
企業コードCOYA
上場日Dec 29, 2022
最高経営責任者「CEO」Swaminathan (Arun)

Coya Therapeutics Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Howard Berman, Ph.D.
Dr. Howard Berman, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
10.00K
--
Dr. Anabella Villalobos, Ph.D.
Dr. Anabella Villalobos, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Independent Director
Independent Director
10.00K
-175.57%
Dr. Fred Grossman
Dr. Fred Grossman
President, Chief Medical Officer
President, Chief Medical Officer
2.71K
--
Mr. David S. Snyder
Mr. David S. Snyder
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Dieter Weinand
Mr. Dieter Weinand
Independent Director
Independent Director
--
--
Mr. Wilbur L. Ross
Mr. Wilbur L. Ross
Independent Director
Independent Director
--
--
Dr. Arun Swaminathan, Ph.D.
Dr. Arun Swaminathan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Mark H. Pavao
Mr. Mark H. Pavao
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Howard Berman, Ph.D.
Dr. Howard Berman, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
10.00K
--
Dr. Anabella Villalobos, Ph.D.
Dr. Anabella Villalobos, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Independent Director
Independent Director
10.00K
-175.57%
Dr. Fred Grossman
Dr. Fred Grossman
President, Chief Medical Officer
President, Chief Medical Officer
2.71K
--
Mr. David S. Snyder
Mr. David S. Snyder
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Independent Director
Independent Director
--
--

よくある質問

Coya Therapeutics Incの上位5名の株主は誰ですか?

Coya Therapeutics Incの上位5名の株主は以下のとおりです。Dr. Howard Berman, Ph.D.

Coya Therapeutics Inc(COYA)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Coya Therapeutics Incの株式を保有している機関は88社あり、保有株式の総市場価値は約8.58Mで、全体の36.58%を占めています。2025Q4と比較して、機関の持ち株は3020350.00増加しています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。